Unlike the complete PRC2 loss during tumor initiation, pharmacological inhibition seems to elicit a cell-cycle restriction also in the most aggressive Kras;Trp53 background, and, importantly, it does not lead to the development of molecular features such as EMT and mucinous differentiation, indicators of tumor progression, that have been observed in the autochthonous models. This evidence concerns the gene KRAS and neoplasm.